<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="Publisher" Owner="NLM">        <PMID Version="1">29525489</PMID>        <DateRevised>            <Year>2018</Year>            <Month>09</Month>            <Day>02</Day>        </DateRevised>        <Article PubModel="Print-Electronic">            <Journal>                <ISSN IssnType="Electronic">1440-1592</ISSN>                <JournalIssue CitedMedium="Internet">                    <PubDate>                        <Year>2018</Year>                        <Month>Mar</Month>                        <Day>07</Day>                    </PubDate>                </JournalIssue>                <Title>Allergology international : official journal of the Japanese Society of Allergology</Title>                <ISOAbbreviation>Allergol Int</ISOAbbreviation>            </Journal>            <ArticleTitle>Identification of Cha o 3 homolog Cry j 4 from Cryptomeria japonica (Japanese cedar) pollen: Limitation of the present Japanese cedar-specific ASIT.</ArticleTitle>            <ELocationID EIdType="pii" ValidYN="Y">S1323-8930(18)30009-1</ELocationID>            <ELocationID EIdType="doi" ValidYN="Y">10.1016/j.alit.2018.02.004</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">About one-third of the Japanese population suffers from Japanese cedar pollinosis, which is frequently accompanied by Japanese cypress pollinosis. Recently, a novel major Japanese cypress pollen allergen, Cha o 3, was discovered. However, whether a Cha o 3 homolog is present in Japanese cedar pollen remains to be determined.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Western blot analysis was performed using Cha o 3-specific antiserum. In addition, cloning of the gene encoding Cry j 4 was conducted using total cDNA from the male flower of Japanese cedar trees. Allergen potency and cross-reactivity were investigated using a T-cell proliferation assay, basophil activation test, and ImmunoCAP inhibition assay.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">A low amount of Cha o 3 homolog protein was detected in Japanese cedar pollen extract. The deduced amino acid sequence of Cry j 4 showed 84% identity to that of Cha o 3. Cross-reactivity between Cry j 4 and Cha o 3 was observed at the T cell and IgE levels.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Cry j 4 was discovered as a counterpart allergen of Cha o 3 in Japanese cedar pollen, with a relationship similar to that between Cry j 1-Cha o 1 and Cry j 2-Cha o 2. Our findings also suggest that allergen-specific immunotherapy (ASIT) using Japanese cedar pollen extract does not induce adequate immune tolerance to Cha o 3 due to the low amount of Cry j 4 in Japanese cedar pollen. Therefore, ASIT using Cha o 3 or cypress pollen extract coupled with Japanese cedar pollen extract is required in order to optimally control allergy symptoms during Japanese cypress pollen season.</AbstractText>                <CopyrightInformation>Copyright Â© 2018 Japanese Society of Allergology. Production and hosting by Elsevier B.V. All rights reserved.</CopyrightInformation>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Osada</LastName>                    <ForeName>Toshihiro</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Ibaraki, Japan; Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Fukuoka, Japan. Electronic address: toshi-osada@taiho.co.jp.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Tanaka</LastName>                    <ForeName>Yuki</ForeName>                    <Initials>Y</Initials>                    <AffiliationInfo>                        <Affiliation>Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Ibaraki, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Yamada</LastName>                    <ForeName>Akira</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Cancer Vaccine Development Division, Kurume University Research Center for Innovative Cancer Therapy, Fukuoka, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sasaki</LastName>                    <ForeName>Eiji</ForeName>                    <Initials>E</Initials>                    <AffiliationInfo>                        <Affiliation>Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Ibaraki, Japan.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Utsugi</LastName>                    <ForeName>Teruhiro</ForeName>                    <Initials>T</Initials>                    <AffiliationInfo>                        <Affiliation>Discovery and Preclinical Research Division, Taiho Pharmaceutical Co., Ltd., Ibaraki, Japan.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>03</Month>                <Day>07</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Allergol Int</MedlineTA>            <NlmUniqueID>9616296</NlmUniqueID>            <ISSNLinking>1323-8930</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Allergen</Keyword>            <Keyword MajorTopicYN="N">Cedar pollen</Keyword>            <Keyword MajorTopicYN="N">Cha o 3</Keyword>            <Keyword MajorTopicYN="N">Cry j 4</Keyword>            <Keyword MajorTopicYN="N">Japanese cedar pollinosis</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>09</Month>                <Day>29</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="revised">                <Year>2018</Year>                <Month>01</Month>                <Day>10</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>01</Month>                <Day>28</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>3</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>3</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>3</Month>                <Day>12</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>aheadofprint</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">29525489</ArticleId>            <ArticleId IdType="pii">S1323-8930(18)30009-1</ArticleId>            <ArticleId IdType="doi">10.1016/j.alit.2018.02.004</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>